Introduction {#s1}
============

The post-translational modification by SUMO is an essential regulatory mechanism of protein function that is involved in most challenges faced by eukaryotic cells, ranging from cell communication to gene expression ([@bib15]; [@bib22]). Mammals express three functional SUMO proteins, SUMO1 and SUMO2/3, with the latter two being almost identical. The sumoylation machinery is composed of an E1 SUMO enzyme (the SAE1/SAE2 heterodimer), a unique E2 SUMO enzyme (UBC9), and E3 SUMO enzymes that enhance SUMO conjugation of specific targets. The steady-state levels of sumoylated substrates are critically regulated by the action of desumoylating enzymes, such as SENPs. Sumoylation is characterized by its highly dynamic and reversible nature, resulting in only a very small fraction of a given protein substrate being sumoylated in the cell at steady state level ([@bib43]). Whereas the vast majority of SUMO substrates identified so far in proteomic analysis are nuclear, a number of cytosolic and plasma membrane proteins can also be targeted by SUMO ([@bib26]). Cellular sumoylation levels relies on the fine equilibrium between conjugating and deconjugating activities and perturbation in this balance has been associated with disease processes, including cancer ([@bib49]) and infections by pathogenic micro-organisms ([@bib35]; [@bib52]). However, while information on the specific roles of the different SUMO E3 and SENP enzymes is accumulating, our knowledge of possible mechanisms regulating the global sumoylation/desumoylation equilibrium still remains highly fragmentary.

Post-translational modifications enable cells to dynamically react to stress or pathogenic agents by modifying quickly, locally and specifically the activity of key proteins. Highjack of protein post-translational modifications is emerging as a key strategy used by pathogens to survive and usurp the cellular machinery to their own benefit ([@bib47]). Whereas the interplay between SUMO and viral infection is relatively well characterized ([@bib20]; [@bib35]), the molecular mechanisms by which sumoylation acts to limit bacterial infection are poorly characterized. *Listeria monocytogenes* facilitates its infection capacity by inducing both a proteasome-dependent and -independent decrease in the amount of SUMO conjugates in host cells. This effect has been attributed to the pore-forming toxin LLO that is sufficient to induce a proteasome-independent degradation of UBC9 ([@bib47]). Another study indicates that the enteropathogenic bacteria *Salmonella* Typhimurium affects sumoylation through upregulation of two microRNAs, miR30c and miR30e, that post-transcriptionally repress UBC9 ([@bib54]). Conversely, it has been reported that two human pathogenic bacteria, *Anaplasma phagocytophilum* and *Ehrlichia chaffeensis*, promote SUMO modification of their own effectors to facilitate their intracellular survival ([@bib5]; [@bib18]). Finally, we have shown recently that, at early stage of infection, *Shigella* can alter either positively or negatively the sumoylation status of a restricted set of transcriptional regulators involved in inflammation ([@bib23]).

In most cases, pathogenic micro-organisms manipulate sumoylation through interference with the SUMO enzymatic machinery. However the precise mechanisms by which pathogenic bacteria subvert the SUMO pathway enzymes and the nature of the relevant host SUMO substrates remain largely unknown. Here, we analyzed the sumoylation status of host proteins at late stage of *Shigella* infection that revealed a dramatic decrease in the global amount of SUMO conjugates in epithelial cells. Mechanistically, we demonstrate that this effect is, in large part, mediated by a calpain-dependent proteolytic degradation of the E1 SAE2 enzyme. We show that impaired sumoylation activity in host cells favors *Shigella* entry and identified RhoGDIα, a master negative regulator of the biological activities of small Rho GTPases, as an important SUMO substrate used by host cells to limit *Shigella* invasion. This work provides mechanistic insight into how sumoylation, by counteracting cytoskeletal rearrangement, impairs bacterial infection. In addition, it establishes calcium signaling as a novel and potent regulator of cellular sumoylation that may be relevant to transiently and/or locally alter sumoylation levels in several normal or disease states.

Results {#s2}
=======

*Shigella* infection inhibits sumoylation in epithelial cells in vitro and in the gut {#s2-1}
-------------------------------------------------------------------------------------

To investigate the impact of *Shigella* infection on global sumoylation of host cell proteins, we followed the global pattern of proteins conjugated to SUMO1 and SUMO2/3 at timed intervals after infection (0 to 180 min). A gradual decrease in both SUMO1 and SUMO2/3 conjugates was observed in HeLa cells infected with the invasive *Shigella* strain M90T. An almost complete disappearance of the higher molecular weight SUMO species was visible after 180 min ([Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). These data are in agreement with a recent report showing impaired sumoylation in similar conditions ([@bib50]). A weak, yet consistent reduction in the level of SUMO1-modified proteins was readily visible 30 min post-infection as shown by a \~ 25% decrease in the total amount of SUMO1 conjugates and a concomitant \~20% accumulation of free SUMO1 ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"} and [Figure 1---figure supplement 1---source data 1](#fig1s1sdata1){ref-type="supplementary-material"}). The decrease in the total amount of SUMO2 conjugates after 30 min was, in contrast, more pronounced ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}), a finding in line with the higher dynamics of modification by SUMO2 compared to SUMO1 ([@bib48]). Of note, no accumulation of free SUMO2/3 could be detected in our setting. SUMO1 and SUMO2/3 conjugates decreased in a multiplicity-of-infection-dependent manner ([Figure 1B](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). This loss in SUMO conjugates was not observed in cells infected with the non-invasive *mxiD* mutant that lacks expression of the type III secretion system (T3SS) ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). Moreover, the global reduction in protein sumoylation was impaired in cells treated with cytochalasin D, a drug that prevents actin polymerization and thereby completely blocks *Shigella* entry. This indicates that actin cytoskeleton rearrangements are required for *Shigella* to impair sumoylation ([Figure 1---figure supplement 1E--G](#fig1s1){ref-type="fig"} and and [Figure 1---figure supplement 1---source data 1](#fig1s1sdata1){ref-type="supplementary-material"}). We then validated the decrease in sumoylation on the two heavily sumoylated RanGAP1 and PML-IV substrates. In *Shigella*-infected HeLa cells, a reduction in sumoylated RanGAP1 was visible 90 min post-infection ([Figure 1D--E](#fig1){ref-type="fig"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). Similar results were obtained in HT1080 cells stably expressing PML-IV where a significant decrease in SUMO-modified form of PML-IV occurred after 120 min infection ([Figure 1F--G](#fig1){ref-type="fig"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). The hyposumoylation was more pronounced for PML-IV than for RanGAP1, in accordance with the high stability of the sumoylation state of RanGAP1.

![*Shigella* infection induces a massive loss in SUMO conjugates in vitro and in vivo.\
(**A**) SUMO1-conjugated protein patterns from uninfected HeLa cells or cells infected with the wild-type *Shigella* strain M90T for the indicated times. Immunoblot analysis was performed on whole-cell lysates using antibodies specific for SUMO1 isoform and tubulin. p-i: post-infection. (**B**) SUMO1-conjugated protein patterns from uninfected HeLa cells or cells infected with *Shigella* for 120 min at the indicated multiplicity of infection (MOI). (**C**) Global SUMO1 patterns of uninfected HeLa cells or cells infected with M90T or the *mxiD* non-invasive *Shigella* for 120 min. (**D**) Immunoblot analysis of RanGAP1 and SUMO-RanGAP1 levels in HeLa cells infected with M90T for the indicated times. (**E**) Quantification of the immunoblot signals are presented as SUMO-RanGAP1 signal relative to unmodified RanGAP1 signal (mean of four independent experiments ± s.d., \*p\<0.05, \*\*p\<0.01). (**F**) Immunoblot analysis of PML-IV and SUMO-PML-IV levels in HT1080 cells stably expressing GFP-PML-IV and infected with M90T for the indicated times. (**G**) Quantification of the immunoblot signals are presented as SUMO-PML-IV signal relative to unmodified GFP-PML-IV signal (mean of three independent experiments ± s.d., \*p\<0.05, \*\*\*p\<0.001). (**H**) Global SUMO1 patterns of the whole intestine of 4-day-old newborn mice (\#1 and \#2), 180 min after inoculation of the invasive M90T strain or the non-invasive *mxiD* mutant. Physiological water was used as a control. Tubulin was used as a loading control. (**I**) Fluorescence microscopy analysis of the intestinal epithelium on paraffin sections after *Shigella* infection of newborn mice for 180 min. Physiological water was used as a control. SUMO2/3 appears in red, auto-fluorescence of the intestinal tissue in green and nuclei counterstained with DAPI in blue. White square, inset.\
10.7554/eLife.27444.006Figure 1---source data 1.Quantification of the immunoblot signals relative to [Figure 1D--G](#fig1){ref-type="fig"}.](elife-27444-fig1){#fig1}

To identify putative *Shigella* factors involved in the decrease in sumoylation, we tested a panel of mutant strains that affect bacterial virulence to various degrees for their ability to induce a loss in SUMO conjugates ([Figure 1---figure supplement 2A--C](#fig1s2){ref-type="fig"}). Among these mutants, the *mxiE* strain, that is defective for the expression and secretion of several important *Shigella* effectors (OspB, OspC1, OspD2, OspD3, OspE1, OspE2, OspF, OspG, VirA, IpaH1.4, IpaH4.5, IpaH7.8 and IpaH9.8) ([@bib8]; [@bib29]; [@bib36]), was still able to induce a decrease in sumoylated proteins, indicating that these different factors are not involved in sumoylation inhibition ([Figure 1---figure supplement 2A--B](#fig1s2){ref-type="fig"}). In a similar manner, mutation in the genes encoding the VirA, IpgD or OspG effectors did not affect the ability of *Shigella* to induce hyposumoylation ([Figure 1---figure supplement 2A--C](#fig1s2){ref-type="fig"}). In contrast, mutants for the expression of the translocator components IpaB and IpaC failed to induce a loss in SUMO conjugates, suggesting that the insertion of these bacterial proteins into the host plasma membrane is necessary to impair sumoylation ([Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}). We next analysed the effect of two insertion mutants of IpaC: *ipaC*/pC351 and *ipaC*/pC57 ([@bib42]). The *ipaC/*pC351 mutant strain is unable to induce actin foci formation and to invade host cells, whereas *ipaC/*pC57 is still able to form actin foci but is not able to efficiently invade host cells ([@bib42]). Only the *ipaC/*pC57 mutant was able to induce hyposumoylation ([Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}), suggesting that, beyond pore formation, the stress induced by the bacteria at the plasma membrane actively contributes to the loss of sumoylation, while not requiring efficient invasion of host cells. Altogether, these results suggest that *Shigella* induces a loss in SUMO conjugates by triggering pore formation and subsequent plasma membrane stress.

To then see whether the findings obtained in vitro may transpose in vivo, we analyzed the SUMO patterns in the gut of newborn mice after 180 min infection with *Shigella*. A decrease in the amount of SUMO1-modified proteins together with an increase in free SUMO1 was clearly visible in mice infected with the invasive strain M90T compared to control or *mxiD*-infected animals ([Figure 1H](#fig1){ref-type="fig"}). Moreover, immunofluorescence staining of SUMO2/3 on paraffin-embedded sections of intestines from M90T-infected newborn mice showed a marked decrease in SUMO2/3 staining in enterocyte nuclei compared to that observed in control newborn mice ([Figure 1I](#fig1){ref-type="fig"}). Altogether these results show that *Shigella* severely impairs sumoylation in vitro and that this effect occurs in vivo in the target organs of the pathogenic bacteria.

Loss in SUMO conjugates is due to intracellular *Shigella*-induced activation of host calpain proteases {#s2-2}
-------------------------------------------------------------------------------------------------------

To gain insights into the mechanisms by which *Shigella* alters the sumoylation status of host cells, we probed a possible involvement of calpains. Indeed, *Shigella* infection of epithelial cells is known to rapidly activate calpains, a family of cysteine proteases known to cleave a wide range of substrates ([@bib3]). As expected, calpain activation was observed in response to *Shigella* infection as measured by the autolytic maturation process that converts the 30 kDa calpain regulatory subunit Capns1 into a truncated 18 kDa fragment ([Figure 2A](#fig2){ref-type="fig"}). In addition, we observed the degradation of the calpain endogenous inhibitor calpastatin ([Figure 2A](#fig2){ref-type="fig"}). Remarkably, pre-treatment of cells by the calpain inhibitor MDL28170 ([@bib38]) entirely abrogated the loss of SUMO1- and SUMO2/3-conjugates upon *Shigella* infection ([Figure 2A](#fig2){ref-type="fig"}). In contrast, and in agreement with a previous report ([@bib3]), *Shigella*-induced calpastatin degradation was not suppressed by MDL28170 treatment, suggesting the involvement of another type of protease for its degradation. We then used two other systems for inhibiting calpain activity. Infection by *Shigella* of cells treated with siRNAs against Capns1 or infection of mouse embryonic fibroblasts (MEFs) knock-out for *Capns1* (*Capns1 KO*) similarly failed to trigger a loss in SUMO conjugates when compared to control cells ([Figure 2B and C](#fig2){ref-type="fig"}).

![*Shigella* inhibits sumoylation by a calpain-dependent mechanism.\
(**A**) HeLa cells were pretreated by vehicle (DMSO) or 100 μM MDL28170 for 1 hr and then left uninfected or infected with the M90T strain or the *mxiD* mutant for 2 hr. Immunoblot analysis were performed using anti-Capns1 (Calpain small subunit 1), -calpastatin, -SUMO1, -SUMO2/3 and -tubulin antibodies. The 18 kDa truncated Capns1 fragment is indicated by an arrow. (**B**) HeLa cells were treated with control siRNA (siScr) or Capns1 siRNA and then left uninfected or infected with the M90T strain or the *mxiD* mutant for 2 hr. Immunoblot analysis were performed using anti-Capns1, -SUMO1, -SUMO2/3 and -tubulin antibodies. (**C**) *Capns1^+/+^* (WT) or *Capns1^−/−^* (KO) MEFs were uninfected or infected with the M90T strain or the *mxiD* mutant for 2 hr. Immunoblot analysis was performed using anti-SUMO1, -SUMO2/3, and -tubulin antibodies.](elife-27444-fig2){#fig2}

Calpain proteases are activated in response to an increase in intracellular calcium levels. It was reported that *Shigella* entry potently induces a local calcium response allowing cytoskeletal remodeling at early invasion stages. Shortly thereafter, it induces a global rise in calcium levels that enhances bacterial invasion and dissemination ([@bib9]). We thus assessed the direct effect of altering calcium levels on *Shigella*-mediated hyposumoylation. Treatment with the calcium-chelating agent BAPTA-AM, that blocks the release of calcium from intracellular stores, was sufficient to avoid calpain protease activation and subsequent loss in SUMO conjugates ([Figure 3A](#fig3){ref-type="fig"}). Conversely, treatment alone with calcium together with the calcium ionophore ionomycin, that increases the intracellular calcium levels, recapitulates the hyposumoylation seen upon *Shigella* infection. Such an effect was visible both at the global or the single substrate level, as exemplified by PML-IV ([Figure 3B--C](#fig3){ref-type="fig"}). Moreover, pre-treatment of the cells with the calpain inhibitor MDL28170 prevented the loss in SUMO conjugates induced by calcium and ionomycin ([Figure 3B--C](#fig3){ref-type="fig"}). Overall, these results demonstrate that increased calcium responses and subsequent calpain activation drives *Shigella*-induced loss of SUMO conjugates, indicating that calcium- and SUMO-dependent signaling are linked.

![Intracellular calcium levels regulate global sumoylation.\
(**A**) HeLa cells were untreated or pretreated with the calcium-chelating agent BAPTA-AM (10 μM) for 1 hr and then left uninfected or infected with the M90T strain for 2 hr. Immunoblot analysis were performed using anti-Capns1, -SUMO1, -SUMO2/3 and -tubulin antibodies. (**B**) HeLa cells were untreated or treated with the calcium ionophore ionomycin (2.5 μM) and increasing doses of CaCl~2~(0.1 to 5 nM) for 30 min, with or without addition of the calpain inhibitor MDL28170 (100 μM). Immunoblot analysis were performed using anti-Capns1, -SUMO1 and -tubulin antibodies. The 18 kDa truncated Capns1 fragment is indicated by an arrow. (**C**) HT1080 cells, stably expressing GFP-tagged PML-IV, were untreated or treated with ionomycin (2.5 μM) and increasing doses of CaCl~2~(0.1 to 5 nM) for 30 min, with or without addition of the calpain inhibitor MDL28170 (100 μM). Immunoblot analysis were performed using anti-GFP, -Capns1 and -tubulin antibodies. The 18 kDa truncated Capns1 fragment is indicated by an arrow.](elife-27444-fig3){#fig3}

SAE2 is a direct calpain substrate {#s2-3}
----------------------------------

As *Shigella* infection leads to a massive decrease in a large number of SUMO conjugates at late time post-infection, we hypothesized that calpain protease activity could target key proteins of the sumoylation machinery. We examined the levels of E1 and E2 SUMO enzymes in HeLa cells upon *Shigella* infection. Whereas the levels of SAE1 and UBC9 were not affected, a strong decrease in the level of SAE2 was observed ([Figure 4A](#fig4){ref-type="fig"}). The degradation of SAE2 triggered by *Shigella* infection was totally abrogated in cells treated with the calpain inhibitor MDL28170 ([Figure 4A](#fig4){ref-type="fig"}). In a similar manner, the loss of SAE2 was prevented in cells transfected with siRNAs against Capns1 or in *Capns1 KO* MEFs ([Figure 4B--C](#fig4){ref-type="fig"}). Thus the E1 enzyme SAE2 is proteolytically degraded by calpains upon *Shigella* infection, leading to the observed massive decrease in SUMO conjugates. Intriguingly, whereas the loss in SAE2 was barely visible before 2 hr post-infection ([Figure 4C](#fig4){ref-type="fig"}), the decrease in global sumoylation started as early as 30 min ([Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}). The mechanisms responsible for the early reduction in SUMO conjugates triggered by *Shigella* infection remain to be elucidated (see Discussion). A direct involvement of increased SENP activities seems unlikely as the loss in SUMO-modified proteins is, like SAE2 loss, strictly dependent on calpains ([Figure 2A--C](#fig2){ref-type="fig"}), and no link has been so far established between calpain and SENP activities. In line with this, we failed to detect any significant desumoylase activities in total non-denatured *Shigella* lysates using fluorogenic 7-amino-4-methylcoumarin SUMO substrates (SUMO1-AMC and SUMO2-AMC) ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} and and [Figure 4---figure supplement 1---source data 1](#fig4s1sdata1){ref-type="supplementary-material"}).

![SAE2 is a direct calpain substrate.\
(**A**) HeLa cells were pretreated by vehicle (DMSO) or 100 μM MDL28170 for 1 hr and then left uninfected or infected with the M90T strain or the *mxiD* mutant for 2 hr. Immunoblot analysis were performed using anti-SAE1, -SAE2 (Ab22104), -UBC9 and -tubulin antibodies. (**B**) HeLa cells were treated with control siRNA (siScr) or Capns1 siRNA and then left uninfected or infected with the M90T strain or the *mxiD* mutant for 2 hr. Immunoblot analysis were performed as in C. (**C**) *Capns1^+/+^* (WT) or *Capns1^−/−^* (KO) MEFs were uninfected (UI) or infected with *Shigella* for the indicated time. Immunoblot analysis were performed as in C. (**D**) Lanes 1--8: HeLa cells were left uninfected or infected with the M90T strain for the indicated times. Lane 9: HeLa cells were pretreated with 100 μM MDL28170 for 1 hr and then infected with the M90T strain in the presence of 100 μM MDL28170 for 3 hr. Immunoblot analysis was performed using a second anti-SAE2 antibody (D15C11). Arrow indicates full length SAE2 and arrowheads indicate SAE2 cleavage products. (**E**) In vitro proteolysis of SAE2 by calpain-1 or calpain-2 visualized by immunoblotting using SAE2 antibody (D15C11). Recombinant SAE2 was incubated with two different concentrations (0.2U or 2U) of calpain-1 or −2 at 30°C for 20 min. Arrow indicates full length SAE2 and arrowheads indicate SAE2 cleavage products.](elife-27444-fig4){#fig4}

Unlike most proteases that result in extensive degradation of proteins, calpains, which recognize the overall conformation of targeted substrate proteins, usually produces large limited-proteolytic fragments cleaved at the boundary of two domains ([@bib51]). The absence of detectable SAE2 proteolytic fragments in immunoblot performed on protein extracts from *Shigella*-infected cells ([Figure 4A--C](#fig4){ref-type="fig"}) suggests that the epitope of SAE2 recognized by our antibody was further cleaved by calpains. By using another SAE2 antibody, that recognizes a peptide localized around a glutamine in position 421, we were able to detect two different SAE2 proteolytic fragments migrating around 85 kDa and 70 kDa in *Shigella*-infected cells ([Figure 4D](#fig4){ref-type="fig"}). This result suggests the existence of at least two major calpain cleavage sites on SAE2. We confirmed this finding in vitro by incubating purified recombinant human SAE2 protein with two different doses of purified calpain-1 (which requires micromolar calcium levels for activation) or calpain-2 (which requires millimolar calcium levels for activation) ([Figure 4E](#fig4){ref-type="fig"}). Incubation of SAE2 with calpain-1 or calpain-2 produced two cleavage products, which are similar in size to those observed in *Shigella*-infected cells. These results identify SAE2 as a novel physiological calpain substrate in vitro and in cells.

Sumoylation limits *Shigella* invasion and the formation of actin-rich foci {#s2-4}
---------------------------------------------------------------------------

We then evaluated the functional consequences of loss of sumoylation on the pathogenicity of *Shigella* in human epithelial cells depleted for UBC9 using siRNAs and tamoxifen-inducible *Ubc9 KO* MEFs ([@bib17]). In a previous study, we reported that a decrease in SUMO conjugation triggered by SAE2 knockdown favored *Shigella* entry into host cells ([@bib23]). In a similar manner, suppression of UBC9 in HeLa cells led to a significant increase in the number of intracellular *Shigella* ([Figure 5A--B](#fig5){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). These results correlate with an increase in *Shigella*-induced actin-rich foci, corresponding to the bacteria entry sites ([Figure 5C--D](#fig5){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). A similar increase in *Shigella* entry and actin polymerization was observed in *Ubc9 KO* MEFs when compared to their wild-type counterparts ([Figure 5E--H](#fig5){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). Of note, no noticable alteration of the actin cytoskeleton could be detected in sumoylation-deficient cells in the absence of *Shigella* infection ([Figure 5---figure supplement 1A--B](#fig5s1){ref-type="fig"}). Thus, lowering host cell sumoylation facilitates *Shigella*-induced cytoskeletal rearrangements and bacterial uptake into host cells.

![Impact of sumoylation on *Shigella* infection.\
(**A**) HeLa cells were treated with siRNAs for UBC9 and SAE2 or a control siRNA (siScr). Immunoblot analysis were performed using anti-SUMO1, -UBC9, -SAE2 and -tubulin antibodies. (**B**) Percentage of *Shigella* internalization upon siRNA-mediated knockdown of UBC9 and SAE2 in HeLa cells relative to control siRNA. Quantification was performed using the gentamicin protection assay (taken siScr value as 100%) 30 min post-infection. Each value is the mean of six independent experiments ± SEM. (**C**) Actin foci formation upon siRNA-mediated knockdown of UBC9 and SAE2 in HeLa cells. Samples were fixed and processed for actin staining 10 min post-infection. The average number of actin foci per cell ±s.d. is indicated (n = 4, at least 50 cells counted per condition). (**D**) Representative images of *Shigella*-induced actin foci in siRNA-treated HeLa cells after 10 min infection. Samples were processed for bacterial LPS (green), actin (red) and nuclei (blue) staining. (**E**) Primary MEFs from *Ubc9^+/+^/T2* (WT) and *Ubc9^fl/-^/T2* (KO) mice ([@bib17]) were treated for 5 days with 4-hydroxy-tamoxifen. Levels of global sumoylation and UBC9 were assessed by immunoblot analysis. Tubulin was used as control. (**F**) Percentage of *Shigella* internalization in *Ubc9* WT and *Ubc9* KO MEFs 30 min post-infection. Quantification is as in B (taken *Ubc9* WT value as 100%). Each value is the mean of nine independent experiments ± SEM. (**G**) Actin foci formation in *Ubc9* WT and *Ubc9* KO MEFS. Samples were fixed and processed for actin staining 10 min post-infection. The average number of actin foci per cell ±s.d. is indicated (n = 3, at least 50 cells counted per condition). (**H**) Representative images of *Shigella*-induced actin foci in *Ubc9* WT or *Ubc9* KO MEFs 10 min post-infection. Samples were processed for bacterial LPS (green), actin (red) and nuclei (blue) staining.\
10.7554/eLife.27444.014Figure 5---source data 1.Percentage of *Shigella* internalization and quantification of the average number of actin foci in cells impaired for sumoylation ([Figure 5B, (C,F and G](#fig5){ref-type="fig"}).](elife-27444-fig5){#fig5}

Sumoylation of RhoGDIα regulates *Shigella* entry {#s2-5}
-------------------------------------------------

To gain molecular insight into how hyposumoylation favors *Shigella* infection, we looked for putative relevant SUMO susbtrates among cytosolic sumoylated proteins identified in previous proteome-wide studies ([@bib23]; [@bib27]). Cellular invasion by *Shigella* is known to require massive rearrangements of the host actin cytoskeleton. We thus focused on Rho GDP-dissociation inhibitor alpha (RhoGDIα) given its important role in actin cytoskeleton dynamics ([@bib24]). Small Rho GTPases are known to be key regulators of actin polymerization and RhoGDIs to down-regulate their biological activity. Notably, RhoGDIα can extract Rho GTPases from membranes and keep them in an inactive state in the cytosol away from their sites of action at membranes. Activation of Rho GTPases family members Rac1, Cdc42 and RhoA is required for *Shigella flexneri* entry process into epithelial cells ([@bib1]; [@bib41]). Interestingly, sumoylation of RhoGDIα on lysine138 (K138) has been shown to increase its binding activity to Rho GTPases thereby restraining their biological activity ([@bib55]). We thus speculated that a decrease in RhoGDIα sumoylation could increase the recruitment of Rho GTPases at plasma membrane, thus facilitating their activation by *Shigella* for its internalization.

As a first step, we analyzed the effect of depleting RhoGDIα on *Shigella* entry and actin polymerization in human epithelial cells. A significant increase in intracellular bacteria was visible 30 min post-infection in RhoGDIα knockdown cells when compared to control cells ([Figure 6A--B](#fig6){ref-type="fig"} and [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). This increase (\~60%) was comparable to the increase seen in cells impaired for sumoylation ([Figure 5B--F](#fig5){ref-type="fig"}). In addition, fluorescence microscopy demonstrated an increased number of actin foci in RhoGDIα-depleted cells in comparison to control cells ([Figure 6C](#fig6){ref-type="fig"}). Hence, suppressing RhoGDIα activity was sufficient to increase the number of *Shigella* entry sites. Next, to study the impact of sumoylation on RhoGDIα activity in *Shigella* pathogenesis, we compared the effect of wild-type RhoGDIα to that of the corresponding SUMO-deficient mutant (RhoGDIα K138R) ([@bib55]) on actin foci formation. Of note, this sumoylation site, that obbeys the canonical consensus motif ψ--K--X--E (where ψ is a large hydrophobic residue), is evolutionarily conserved, suggesting that it may be an important feature of RhoGDIα regulatory function ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). We took advantage of the fact that both RhoGDIα plasmids lack the 3\'-UTR sequence to design a 3\'-UTR-targeting siRNA that silenced only endogenous RhoGDIα. Restoration experiments using either GFP-tagged wild-type RhoGDIα or K138R mutant were performed in HeLa cells knockdown for endogenous RhoGDIα ([Figure 6D](#fig6){ref-type="fig"}). Although the knockdown efficiency of the 3\'-UTR-targeting siRNA was not total (\~60% knockdown), significantly higher number of *Shigella*-induced actin foci was observed by fluorescence microscopy in cells expressing RhoGDIα K138R, compared to that observed in cells expressing the wild type form ([Figure 6E--F](#fig6){ref-type="fig"} and [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). This result demonstrates that impaired sumoylation of RhoGDIα favors *Shigella* entry and could thus contribute to the increased infectivity observed in sumoylation-deficient cells.

![Sumoylation of RhoGDIα regulates *Shigella* internalization in epithelial cells.\
(**A**) HeLa cells were treated with siRNA for RhoGDIα or a control siRNA (siScr). Immunoblot analysis was performed using anti-RhoGDIα and -tubulin antibodies. (**B**) Percentage of *Shigella* internalization upon siRNA-mediated knockdown of RhoGDIα relative to control siRNA. The percentage of internalized bacteria was quantified using the gentamicin protection assay (taken siScr value as 100%) 30 min post-infection. Each value is the mean of eleven independent experiments ± SEM. (**C**) Representative images of *Shigella*-induced actin foci in siRNA-treated HeLa cells after 10 min infection. Samples were processed for bacterial LPS (green), actin (red) and nuclei (blue) staining. (**D**) Hela cells co-transfected with siRhoGDIα (targeting the 3'UTR) together with either GFP-tagged sRhoGDIα WT or GFP-tagged RhoGDIα K138R. Immunoblotting was performed using a RhoGDIα antibody. Arrows indicate GFP-tagged and endogenous RhoGDIα proteins. (**E**) Hela cells co-transfected as in D and infected with M90T for 10 min. Samples were fixed and processed for actin staining 10 min post-infection. The average number of actin foci per cell ±s.d. is indicated (n = 4, at least 50 cells counted per condition). (**F**) Representative images of *Shigella*-induced actin foci in HeLa cells co-transfected as in D with GFP-tagged RhoGDIα constructs (green) after 10 min infection. Samples were processed for actin (red) and nuclei (blue) staining. (**G**) Immunoblot analysis was performed on whole-cell lysates or plasma membrane fractions (recovered by ultracentrifugation) from *Ubc9* WT or *Ubc9* KO MEFs using anti-Cdc42, -RhoA, -Rac1, - RhoGDIα, -UBC9 and -tubulin antibodies. (**H**) Quantification of the immunoblot signals obtained from *Ubc9* WT or *Ubc9* KO MEF protein extracts are presented as RhoGTPase signal (Cdc42, RhoA or Rac1, as indicated on the x-axis) relative to tubulin signal (mean of five independent experiments ± s.d.).\
10.7554/eLife.27444.017Figure 6---source data 1.Source data file relative to [Figure 6B, E and H](#fig6){ref-type="fig"}.](elife-27444-fig6){#fig6}

To next assess whether sumoylation inhibition impacts the RhoGDIα inhibitory function on Rho GTPase activity, we analyzed the membrane localization of three Rho GTPases (RhoA, Cdc42 and Rac1) in non-infected *Ubc9 WT* and *Ubc9 KO* MEFs. It has been shown that depletion of RhoGDIα, although it decreases the protein levels of the Rho GTPAses through a destabilization process, it significantly increases the proportion of membrane-bound active Rho GTPases ([@bib10]). Enrichment in the cell membrane fraction using ultracentrifugation revealed that, despite similar amounts of GTPases in total protein extracts, a modest yet significant increase in the amount of membrane-bound Rho GTPases was visible in sumoylation-deficient MEFs, relative to wild-type MEFs ([Figure 6G--H](#fig6){ref-type="fig"} and [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). These results indicate that loss of sumoylation favors accumulation of Rho GTPases at the plasma membrane, thus providing a supportive environment for *Shigella* entry into host cell.

Endogenous RhoGDIα and SUMO proteins are recruited at bacteria entry sites and *Shigella* rapidly impairs RhoGDIα sumoylation {#s2-6}
-----------------------------------------------------------------------------------------------------------------------------

The RhoGDI--Rho GTPase complex has been shown to shuttle between the cytosol and the membrane ([@bib24]). To thus visualize the potential recruitment of engodenous SUMO to the sites of bacterial entry, we performed immunofluorescence experiments in *Shigella-*infected *Ubc9 WT* MEFs using SUMO1 and SUMO2/3 antibodies. A consistant enrichment of both SUMO1 and SUMO2/3 was observed at the actin-rich foci soon after infection ([Figure 7A--D](#fig7){ref-type="fig"}, upper panels and black bars, and [Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}). Similar findings were obtained in infected HeLa cells ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Immunostaining for SUMO1 and SUMO2/3 performed in *Ubc9 KO* MEFs revealed a significant decrease in SUMO signal at the *Shigella* entry sites. This finding indicates that the presence of SUMO at actin foci in *Ubc9 WT* MEFs corresponds to SUMO-conjugated proteins and not to free SUMO1 or SUMO2/3 ([Figure 7A--D](#fig7){ref-type="fig"}, lower panels and white bars). We then looked at the distribution of RhoGDIα upon *Shigella* infection. This revealed a noticable enrichment at actin-rich foci in *Ubc9 WT* MEFs. Such an accumulation is still observable in the sumoylation-deficient *Ubc9 KO* MEFs, suggesting that sumoylation does not impact RhoGDIα recruitment to plasma membrane ([Figure 7E--F](#fig7){ref-type="fig"} and [Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}).

![Endogenous RhoGDIα and SUMO are localized at *Shigella*-induced actin foci.\
(**A**) SUMO1 accumulates at *Shigella* (M90T) entry sites. Representative ApoTome-generated micrographs of *Shigella*-infected *Ubc9* WT or *Ubc9* KO MEFs after 10 min infection. Samples were fixed and processed for immunostaining using anti-SUMO1 antibody (green) and staining of actin (red) and nuclei (blue) (white square, inset). (**B**) The Pearson's coefficient (Rr) was used to measure the signal intensity correlation between SUMO1 and *Shigella*-induced actin foci stainings. Data are means ±SEM (at least 40 foci analyzed per condition). p value calculated as described in Materials and Methods. (**C**) SUMO2/3 accumulates at *Shigella* (M90T) entry sites. Same as in A using a SUMO2/3 antibody. (**D**) Same as in B with SUMO2/3 signal. (**E**) Recruitment of RhoGDIα is at *Shigella* (M90T) entry sites. Same as in A using a RhoGDIα antibody. (**F**) Same as in B with RhoGDIα signal. NS: non significant.\
10.7554/eLife.27444.020Figure 7---source data 1.Source data files relative to [Figure 7B, D and F](#fig7){ref-type="fig"}.](elife-27444-fig7){#fig7}

Finally, we assessed whether the global loss of SUMO conjugates induced by *Shigella* infection translates into a similar decrease in the sumoylation state of endogenous RhoGDIα. Immunoprecipitation followed by western blotting in uninfected cells revealed, in addition to the unmodified \~25 kDa RhoGDIα, a \~40 kDa RhoGDIα species, which was detected by two different anti-SUMO1 antibodies (Y299 and 21C7 clones), indicating SUMO-modified RhoGDIα ([Figure 8](#fig8){ref-type="fig"}). We then investigated the impact of *Shigella* infection on RhoGDIα sumoylation with time. Whereas the levels of unmodified RhoGDIα remained unaffected, we observed the complete disappearance of SUMO-RhoGDIα as quickly as 30 min post-infection ([Figure 8](#fig8){ref-type="fig"}). The reduction in the global amount of SUMO1 conjugates was only moderate in these conditions ([Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), indicating that RhoGDIα is highly sensitive to sumoylation inhibition.Thus, RhoGDIαis a *bona fide* SUMO substrate in vivo and SUMO-modified RhoGDIαis rapidly lost upon *Shigella* infection.

![*Shigella* infection leads to loss in SUMO- RhoGDIα.\
Endogenous RhoGDIα is modified by SUMO1 and rapidly desumoylated upon *Shigella* infection. Whole-cell extracts harvested from uninfected or *Shigella* (M90T)-infected Hela cells (from 0 to 120 min post-infection) were subjected to immunoprecipitation (IP) using anti-RhoGDIα or control IgG. Immunoprecipitates (left panel) and input lysates (right panel) were analysed by immunoblot analysis using anti-RhoGDIα, and -SUMO1 (clones Y299 and 21C7) antibodies. Arrowhead indicates unmodified RhoGDIα and arrow indicates SUMO1- RhoGDIα.](elife-27444-fig8){#fig8}

Discussion {#s3}
==========

Pathogenic organisms possess the remarkable ability to exploit post-translational modification mechanisms to modulate host factors for their own survival and propagation. Whereas some bacterial pathogens have been shown to alter the sumoylation of host proteins, the mechanisms through which the bacteria interfere with the SUMO machinery and the identity of the SUMO targets remain largely undefined. In this study, we show that *Shigella* induces a massive decrease in SUMO1 and SUMO2/3 conjugates at late time post-infection in epithelial cells in culture and in the intestinal mucosa. This global loss in sumoylation relies on activation of calpain proteases that target the SUMO E1 enzyme SAE2 for degradation, thus leading to sumoylation inhibition. In addition, we show that SUMO-modified RhoGDIα is rapidly lost upon *Shigella* infection favoring cytoskeletal rearrangements and bacterial entry. To our knowledge, this is the first characterization of a SUMO substrate targeted by bacteria to enhance infectivity. Thus, in addition to identifying sumoylation of RhoGDIα as an important event counteracting cytoskeletal remodeling and bacterial entry, our work reveals the ability of calcium signals to control global sumoylation levels.

Calpain proteases constitute a family of calcium-dependent cysteine proteases involved in a wide range of cellular functions, including cytoskeletal rearrangements, apoptosis and cell survival ([@bib45]). An increase in free intracellular calcium is required to induce the calpain conformational changes necessary for their activity and substrate recognition. Upon host cell invasion, *Shigella* induces both local and global calcium responses. Whereas the local calcium response at *Shigella* entry sites peaks at 15 min post-infection, a global increase in calcium signaling is observed shortly thereafter ([@bib9]). Local elevation of intracellular calcium levels at early stage leads to calpain activation that affects the dynamics of cytoskeletal reorganization to promote *Shigella* invasion. At later stage, global calcium responses associated with sustained calpain activation leads to slow necrotic cell death ([@bib3]). Our findings that inhibiting either intracellular calcium influx or calpain activity prevented *Shigella*-induced loss of SUMO-conjugates and, conversely, that the sole treatment with calcium and ionomycin in the absence of *Shigella* triggered sumoylation inhibition indicate that increased cytosolic calcium and subsequent calpain activation are responsible for SAE2 degradation and impairment of sumoylation. To our knowledge, a single study describing a putative role of calpains in the modulation of specific sumoylation events has been reported. In this work, forced expression of calpain three was shown to lead to the cleavage the SUMO E3 ligase PIAS3 and subsequent inhibition of its enzymatic activity ([@bib16]). A recent study reported that HeLa cells infected by *Shigella* show reduced sumoylation together with a slight decrease in UBC9 protein levels ([@bib50]). We repeatedly failed to detect any decrease in the amount of UBC9 following *Shigella* infection whereas SAE2 was systematically found to be lost. The reason for this discrepancy remains unknown. Using a panel of *Shigella* strains mutated for a series of bacterial effectors, we show that mutants lacking the ability to elicit a stress response at the plasma membrane, as detected by actin foci formation, are no longer able to trigger loss of SUMO conjugates. Calpain proteases have been shown to be activated by plasma membrane injuries in order to contribute to membrane repair ([@bib25]; [@bib39]; [@bib40]). One may thus hypothesize that, by triggering pore formation and subsequent plasma membrane stress, *Shigella* infection induces a calpain-dependent loss of sumoylation.

Current knowledge of the mechanisms through which bacteria interfere with the SUMO enzymatic machinery remains largely limited. To date, a unique example of a pathogen protein targeting the SAE1/SAE2 heterodimer is the adenoviral protein Gam1 that recruits SAE1/SAE2 to the Cullin2/5-EloB/C-Roc1 ubiquitin ligase complex, thus leading to SAE1 ubiquitin-dependent degradation ([@bib7]). By contrast, the majority of bacteria known to interfere with sumoylation have been shown to target the E2 conjugating enzyme UBC9 ([@bib52]). *Salmonella* Typhimurium depletes UBC9 in infected cells by upregulating the expression of two microRNAs (miR30c and miR30e) that affect UBC9 transcript stability ([@bib54]). Another example is the Gram-positive bacteria *Listeria monocytogenes* that leads to decreased sumoylation together with UBC9 degradation. Whereas MG132, that inhibits proteasomal degradation but also calpain activity ([@bib34]), partially restored the profile of sumoylated proteins in infected cells, it failed to prevent UBC9 degradation ([@bib47]). The mechanisms underlying these two apparently paradoxical findings remain to be identified. The secretion of the pore-forming toxin (PFT) LLO triggers UBC9 degradation and this bacterial toxin alone can recapitulate the decrease in sumoylation observed during *Listeria* infection. Moreover, this effect on host cells has also been observed for PFTs from other Gram-positive bacteria, such as PFO and PLY ([@bib47]). It is possible that, upon *Shigella* infection, the translocator-forming IpaB and IpaC proteins, by inducing a stress at the plasma membrane, act in a similar manner. In this context, it will be interesting to investigate whether the abilities of the Gram-positive bacteria PFTs to decrease host sumoylation might be linked to calpain activation since many PFTs, including LLO, are described to activate these proteases by elevating intracellular calcium levels ([@bib6]).

A common theme in the pathogenicity of bacteria is the manipulation of host cells by targeting the cytoskeleton for their own needs ([@bib2]). Among the multiple regulation steps of the actin cytoskeleton, bacterial factors interfere preferentially with Rho GTPases either directly *via* covalent modification or through interfacing with regulators of Rho GTPase control. As Rho GTPases are active in the GTP-bound state, several bacteria produce toxins that modulate the nucleotide state of the Rho GTPases for activation or inhibition ([@bib21]). For example, *Shigella* injects into host cells the virulence factors IpgB1 and IpgB2 that activate the Rho GTPases Rac1, Cdc42 and RhoA through their guanine nucleotide exchange factor activity toward these proteins ([@bib31]; [@bib44]). However, few reports have described direct effects of bacterial infection on RhoGDIα activity. One example is the *Yersinia* effector YpkA that mimics eukaryotic RhoGDIα, leading to global Rho GTPase inhibition and cytoskeletal disruption ([@bib46]). We report here that RhoGDIα silencing increases the number of intracellular *Shigella* and actin foci, indicating that RhoGDIαregulatory functions are required to limit *Shigella* entry into host cells. Moreover, sumoylation of RhoGDIα is important for this activity as a SUMO-deficient RhoGDIαmutant shows a reduced ability to impair bacterial entry. These data are consistent with the finding that SUMO-RhoGDIαplays an inhibitory role on actin polymerization ([@bib55]). It is thus tempting to speculate that the rapid loss in SUMO-RhoGDIα triggered by *Shigella* entry could promote de novo infection by extracellular *Shigella* thus amplifying the infection process. Intriguingly, whereas the degradation of SAE2 is hardly visible before 2 hr post-infection, the decrease in SUMO-RhoGDIαoccurs earlier, as soon as 30 min following infection, and coincides with the first visible signs of global hyposumoylation. Since the loss of SAE2 and SUMO conjugates are both calpain-dependent, a possible explanation for these differing kinetics may be that the two events result from the two consecutive waves of calcium responses triggered by *Shigella* infection. Whereas, the second, global calcium response would trigger complete SAE2 degradation, ultimately leading to a generalized loss of SUMO-conjugated proteins, the rapid loss of SUMO-RhoGDIα would most likely result from the first and localized wave of Ca2+ responses induced by *Shigella* in the vicinity of the entry sites. This response would lead to calpain-induced degradation of a small local pull of SAE2, barely detectable by Western blot, and subsequent loss of sumoylated RhoGDIα. Such a local and long-lasting Ca2+ response was shown previously to be confined to bacterial invasion sites, being induced as early as 5 min after bacterial contact with epithelial cells, with a peak response at 15 min ([@bib9]). Moreover, these local calcium responses at Shigella entry sites occur at about 10 μM, a concentration quite compatible with the activation of calpains ([@bib30]). In line with this notion, local calpain activation at the plasma membrane has been extensively described for many membrane-associated substrates, such as FAK, talin, insulin receptor and VE-cadherin ([@bib13]; [@bib53]; [@bib56]). If, as we surmise, sumoylation of RhoGDIαwere indeed to take place in the vicinity of the bacterial entry sites, it is thus likely that the local activation of calpains by an initially localized rise in calcium may lead to SAE2 cleavage and subsequent loss of SUMO-RhoGDIα - and potentially of a limited pool of other SUMO substrates - at *Shigella* invasion sites. A more definitive clarification of this issue must, however, await the development of probes permitting the visualization of localized sumoylation dynamics.

In conclusion, the data presented here describe a novel mechanism by which *Shigella* promotes its own infection capacity by rapidly decreasing the sumoylation state of RhoGDIα. It remains to be determined to which extent the sumoylation of other host substrates can contribute to limit *Shigella* invasion. *Shigella,* however, can also positively modulate sumoylation of a restricted set of substrates. For example, the *Shigella* effector OspF has been described to be sumoylated, favoring its translocation into the nucleus ([@bib28]). Moreover, using a proteomic approach, we found that, whereas *Shigella* mainly induces hyposumoylation at early stage of infection, a small number of cellular substrates also become hypersumoylated ([@bib23]). Clearly, full dissection of the spatio-temporal interplay between *Shigella* and sumoylation will require further investigation.

In addition, our work reveals a previously unknown strategy for modulating the global levels of cellular sumoylation through a calcium/calpain-dependent process that may have important implications in a number of pathological or physiological situations. Calcium signaling is involved in a multitude of biological processes, such as synaptic function, muscle contraction and cardiac activity ([@bib14]). It is thus not surprising that alteration in calcium homeostasis is known to participate in a number of pathological processes including cardiovascular diseases, neurological disorders and cancer ([@bib11]). An interesting challenge in the future will be to probe whether situations associated with changes in cytosolic calcium levels, such as during the sleep-wake cycle ([@bib4]), could translate into the modulation of global cellular sumoylation. Morever, the highly localized nature of calcium signals, as exemplified by the local calcium response confined to the *Shigella* invasion site ([@bib9]), offers the intriguing possibility for localized variations in sumoylation, as shown recently for ubiquitination ([@bib37]).

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------
  Reagent type (species) or\        Designation                         Source or reference         Identifiers
  resource                                                                                          
  --------------------------------- ----------------------------------- --------------------------- ------------------------
  strain, strain background\        M90T strain                         PMID: 6279518               Taxonomy ID: 1086030
  (Shigella flexneri serotype 5a)                                                                   

  strain, strain background\        *mxiD*                              PMID: 8437520               N/A
  (Shigella flexneri serotype 5a                                                                    

  strain, strain background\        mxiE                                PMID: 12142411              N/A
  (Shigella flexneri serotype 5a)                                                                   

  strain, strain background\        ospG                                PMID: 16162672              N/A
  (Shigella flexneri serotype 5a)                                                                   

  strain, strain background\        ipaB                                PMID: 1582426               N/A
  (Shigella flexneri serotype 5a)                                                                   

  strain, strain background\        ipaC                                PMID: 19165331              N/A
  (Shigella flexneri serotype 5a)                                                                   

  strain, strain background\        ipaC/pC57                           PMID: 19165331              N/A
  (Shigella flexneri serotype 5a)                                                                   

  strain, strain background\        ipaC/pC351                          PMID: 19165331              N/A
  (Shigella flexneri serotype 5a)                                                                   

  strain, strain background\        virA                                PMID: 22423964              N/A
  (Shigella flexneri serotype 5a)                                                                   

  strain, strain background\        ipgD                                PMID: 8478058               N/A
  (Shigella flexneri serotype 5a)                                                                   

  cell line (Hela)                  CCL-2                               ATCC                        ATCC CCL2/CVCL_0030

  cell line (HT1080)                CCL-121                             ATCC                        ATCC CCL-121/CVCL_0317

  cell line (HT1080)                GFP-PML-IV                          PMID: 23530056              N/A

  cell line (Hela)                  TAP-SUMO1                           PMID: 25097252              N/A

  cell line (Hela)                  TAP-SUMO2                           PMID: 25097252              N/A

  cell line (HT1080)                UBC9-auxin degron                   this paper                  N/A

  genetic reagent (siRNA)           control                             Dharmacon                   \#D-001810--10

  genetic reagent (siRNA)           Capns1                              Dharmacon                   \#L-009979--00

  genetic reagent (siRNA)           Ubc9                                Dharmacon                   \#L-004910--00

  genetic reagent (siRNA)           SAE2                                Dharmacon                   \#L-005248--01

  genetic reagent (siRNA)           RhoGDIα                             Dharmacon                   \#L-016253--00

  transfected construct (Plasmid)   pEGFP-RhoGDIα WT                    PMID: 22393046              N/A

  transfected construct (Plasmid)   pEGFP-RhoGDIα K138R                 PMID: 22393046              N/A

  antibody                          anti-SAE1                           Abcam                       \#ab97523/AB_10681015

  antibody                          anti-SAE2                           Abcam                       \#ab22104/AB_446785

  antibody                          anti-SUMO1                          Abcam                       Y299/AB_778173

  antibody                          anti-SUMO2/3                        Abcam                       8A2/AB_1658424

  antibody                          anti-UBC9                           Abcam                       EP2938Y/AB_1267373

  antibody                          anti-SUMO1                          DSHB Iowa                   21C7/AB_2198257

  antibody                          anti-Calpastatin                    Cell Signaling Technology   \#4146/AB_2244162

  antibody                          anti-SAE2                           Cell Signaling Technology   D15C11/AB_10889561

  antibody                          anti-Cdc42                          Cell Signaling Technology   11A11/AB_10695738

  antibody                          anti-RhoA                           Cell Signaling Technology   67B9/AB_10693922

  antibody                          anti-Tubulin                        Cell Signaling Technology   DM1A/AB_1904178

  antibody                          anti-RanGAP1                        Santa Cruz                  C-5/AB_2176987

  antibody                          anti-GFP                            Santa Cruz                  C-2

  antibody                          anti-RhoGDIα                        Merck Millipore             \#06--730/AB_310229

  antibody                          anti-Capns1                         Merck Millipore             MAB3083/AB_2070014

  antibody                          anti-Rac1                           Merck Millipore             23A8/AB_309712

  antibody                          anti-LPS                            PMID: 25097252              N/A

  antibody                          anti-SP100                          PMID: 7559785               N/A

  chemical compound, drug           Phalloidin--Tetramethylrhodamine\   Sigma                       P1951 / AB_2315148
                                    B isothiocyanate                                                

  chemical compound, drug           Dapi                                Sigma                       D9542

  chemical compound, drug           Cytochalasin D                      Sigma                       C8273

  chemical compound, drug           MDL 28170                           Sigma                       M6690

  chemical compound, drug           Ionomycin                           Sigma                       I3909

  chemical compound, drug           BAPTA-AM                            Enzo life sciences          BML-CA411-0025

  chemical compound, drug           Indole-3-acetic acid                Sigma                       I5148

  chemical compound, drug           N-Ethylmaleimide                    Sigma                       E3876

  peptide, recombinant protein      Recombinant SAE2                    Novus biologicals           NBP2-50574-20ug

  peptide, recombinant protein      Recombinant Calpain-1               Merck Millipore             208712

  peptide, recombinant protein      GST-SENP2cat                        this paper                  NP_06760.2

  peptide, recombinant protein      SUMO1-AMC                           Boston Biochem              UL-551

  peptide, recombinant protein      SUMO2-AMC                           Boston Biochem              UL-758

  software, algorithm               Icy software                        Institut Pasteur            PMID: 22743774
  --------------------------------------------------------------------------------------------------------------------------

Bacterial strains and cell culture {#s4-1}
----------------------------------

*Shigella flexneri* serotype 5a strains were isolated on congo red agar plates. The invasive wild-type strain M90T, its isogenic non-invasive derivative *mxiD* (impaired for T3SS) and isogenic mutants for various effectors (*mxiE*, *ospG*, *ipaB*, *ipaC*, *virA* and *ipgD*) were used. Two strains expressing IpaC variants (*ipaC*/pC57 and *ipaC*/pC351) were also used ([@bib42]). For infection experiments, strains were cultured in BTCS medium (Difco) overnight at 37°C with agitation. Subcultures were performed for 3 hr to reach the exponential phase and resuspended in DMEM medium (Invitrogen). Human cell lines HeLa CCL-2 and HT1080 were obtained from ATCC and grown according to the supplier's recommendations. The HT1080 cell line stably expressing GFP-PML IV, generated in our lab, was maintained as previously reported ([@bib19]). HeLa cells overexpressing TAP-SUMO-1 and TAP-SUMO-2, kindly provided by Ronald T. Hay (University of Dundee, Scotland, UK), were maintained as previously reported ([@bib23]). None of these cell lines belongs to the list of commonly misidentified cell lines (ICLAC). All cell lines cell has been routinely tested for mycoplasma contamination using the PCR Mycoplasma Test Kit II (PromoKine).

siRNA and plasmid transfection {#s4-2}
------------------------------

Hela cells were transfected for 72 hr using Lullaby reagent (OZ biosciences) with siRNA from Dharmacon against Capns1 (\#L-009979--00), UBC9 (\#L-004910--00), SAE2 (\#L-005248--01), RhoGDIα (\#L-016253--00) or control siRNA (\#D-001810--10, Dharmacon) according to the manufacturers'instructions. The pEGFP-RhoGDIα WT or pEGFP-RhoGDIα K138R expression vectors were, respectively, a kind gift from Dr. Mark R. Philips (New York University School of Medicine, New York) and Dr. Chuanshu Huang (New York University School of Medicine, New York). HeLa cells were transfected with plasmids by using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol.

Antibodies and reagents {#s4-3}
-----------------------

For immunoblotting and immunofluorescence experiments we used the following antibodies. Rabbit polyclonal anti-SAE1 (\#ab97523) and anti-SAE2 (\#ab22104), rabbit monoclonal anti-SUMO1 (Y299) and anti-UBC9 (EP2938Y) and mouse monoclonal anti-SUMO2/3 (8A2) were purchased from Abcam. Mouse monoclonal anti-SUMO1 (21C7) was from DSHB Iowa. Rabbit polyclonal anti-Calpastatin (\#4146), rabbit monoclonal anti-SAE2 (D15C11), anti-Cdc42 (11A11) and anti-RhoA (67B9) and mouse monoclonal anti-Tubulin (DM1A) were purchased from Cell Signaling Technology. Mouse monoclonal anti-RanGAP1 (C-5) and anti-GFP (C-2) were purchased from Santa Cruz. Rabbit polyclonal anti-RhoGDIα (\#06--730) and mouse monoclonal anti-Capns1 (MAB3083) and anti-Rac1 (23A8) were purchased from Merck Millipore. Rabbit polyclonal antibodies to *Shigella flexneri* 5a LPS and SP100 ([@bib12]) are home made. TRITC-labelled phalloidin for vizualization of actin cytoskeleton in mammalian cells, Dapi for labelling nuclei and Cytochalasin D for blocking actin cytoskeleton were purchased from Sigma. The calpain inhibitor MDL28170 (Z-Val-Phe-aldehyde) (Sigma) was added at a 100 mM final concentration to the culture medium. Cytochalasin D (Sigma) was added at 15 min prior to infection (5 μM). The calcium ionophore ionomycin (Sigma) and CaCl~2~ (Sigma) were used at indicated doses as calpains inducers. BAPTA-AM (10 μM, Enzo Life Sciences) was used as a cell permeant Ca2+ chelator to inhibit intracellular calpains activity.

Invasion assays {#s4-4}
---------------

Bacterial invasion of human cells and MEFs was performed using gentamycin protection assay ([@bib33]). Epithelial cell monolayers were infected with the indicated moi (multiplicity of infection). After 10 min of centrifugation at 1000 g and a 10 min incubation period at 37°C (5% CO~2~), the infected cells were washed twice with PBS, and fresh cell culture medium containing 50 mg/mL of gentamicin was added for 1 hr. To determine the number of intracellular bacteria, the cell monolayer was washed twice with PBS and lysed with 1% Triton X-100 (Sigma) in PBS, then mixed, diluted and plated onto TCS agar plates to determine the number of colony forming unit (CFU) recovered from the lysed monolayer.

Auxin-inducible impaired sumoylation {#s4-5}
------------------------------------

HT1080 cells, stably expressing UBC9 fused to an auxin-inducible degron were used (manuscript in preparation). Degradation of the expressed UBC9-auxin degron fusion, leading to impaired sumoylation, was induced by adding auxin, indole-3-acetic acid (Sigma; 200 µM final), for 24 hr to the cell culture medium (DMEM + Glutamax, Gibco).

Immunofluorescent staining {#s4-6}
--------------------------

After bacterial infection, cells were fixed with 4% paraformaldehyde (PFA) and immunostained overnight at 4°C, with the indicated specific primary antibodies. A 1 hr incubation with secondary antibodies and/or TRITC-labelled phalloidin was performed at room temperature. To determine the number of actin foci per cell, at least 100 *Shigella*-infected cells were counted. Each microscopy image is representative of at least three independent experiments. Intestinal samples from newborn mice were fixed for 2 hr in 4% PFA and kept in 70% ethanol before paraffin embedding. Microtome sections of 7 μm were prepared. Sections were rehydrated, permeabilized with 0.1% Triton X-100 for 15 min, saturated with Ultra-V-Block (Thermo Scientific) and then incubated overnight at 4°C with SUMO2/3 antibody. After washing, the sections were incubated with a goat anti-rabbit Cy3-conjugated secondary antibody (Jackson Immunotech) for 1 hr at room temperature. Nuclei were counternstained with DAPI, and slides were mounted (Prolong, Life technologies). All images were acquired using Apotome microscope (Zeiss). Pearson's correlation coefficient (Rr) was used as a measure of the co-localization and calculated using the colocalization studio plugin of Icy software ([@bib32]).

Immunoblot analysis {#s4-7}
-------------------

Whole-cell protein extracts were prepared from cell monolayer by adding directly 2x Laemmli sample buffer (Bio-rad). Newborn mice gut was dissected and homogenized in 1 mL of lysis buffer (50 mM Tris-HCl pH8.0, 0,1 mM EDTA, 200 mM NaCl, 0,5% NP40, 10% glycerol, 20 mM N-ethylmaleimide (NEM), 1x Protease inhibitor cocktail tablets (Roche)). Plasma membrane proteins were enriched by harvesting cells in a non-denaturing lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM MgCl~2~, 1 mM EDTA, Protease inhibitor cocktail tablets). Cells were disrupted by sonication (three times on ice), followed by centrifugation for 10 min at 1000 g (4°C) to remove the nuclear fraction (pellet). An ultracentrifugation (90 min at 100 000 g) was then performed on the supernatant, the pellet containing the membrane fraction was resuspended in lysis buffer. Equal amounts of protein were subjected to SDS-PAGE (4--15% Criterion TGX gradient protein gel, Bio-rad), transferred on nitrocellulose membrane (Trans-blot turbo, Bio-rad), and then immunobloted using the indicated primary antibodies. Anti-rabbit and anti-mouse antibodies conjugated with IR800 or IR680 dyes were used as secondary antibodies, and the infrared signal was integrated using an infrared imaging system (LI-COR Odyssey). The bands intensities were calculated using the software associated with the Odyssey system (Image studio).

Immunoprecipitation {#s4-8}
-------------------

For immunoprecipitation of RhoGDIα, cells were lysed in buffer (50 mM Tris-HCl pH 8.0, 0,1 mM EDTA, 200 mM NaCl, 0,5% NP40, 10% glycerol, 20 mM NEM, 1x Protease inhibitor cocktail tablets (Roche)) and incubated for 2 hr at 4°C with anti-RhoGDIα antibody. Immune complexes were collected by incubation for 1 hr at 4°C with ProteinG/A sepharose beads (GE Healthcare) and washed three times in lysis buffer. Whole cell lysate (input) or cell lysates immunoprecipitated with anti-RhoGDIα were subjected to SDS-PAGE followed by immunoblotting with anti-RhoGDIα, anti-SUMO1 and anti-SUMO2/3.

In vitro cleavage of SAE2 by calpain {#s4-9}
------------------------------------

Recombinant SAE2 (Novus biologicals) (10 μg) was digested with two different concentrations of calpain-1 (Merck Millipore; 0.2 and 2 U/mg) in reaction buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 2 mM DTT, 1 mM EDTA, 3 mM CaCl~2~) at 30°C for 20 min. The reaction was stopped by boiling samples for 5 min after the addition of an equal volume of 2X loading sample buffer (Bio-rad). Samples were then subjected to immunoblot analysis.

SUMO-AMC assays {#s4-10}
---------------

For non-denatured *Shigella* lysates, 4 × 10^9^ bacteria were centrifuged and resuspended in 400 µL of lysis buffer (50 mM Tris, 150 mM NaCl, protease inhibitor cocktail (Roche), 0,5% Triton) and then sonicated. DTT was added to the lysate at a final concentration of 5 mM. Bacterial lysate was diluted to 1/10 within reaction buffer (50 mM Tris, 150 mM NaCl, 0,75 mg/mL BSA, 2 mM cysteine and 1 mg/mL Chaps). Recombinant GST fusion of the SENP2 catalytic domain was added in the reaction buffer at a final concentration of 40 nM. SUMO1-AMC or SUMO-2-AMC (Boston Biochem) were added in the diluted sample at a final concentration of 100 nM, in a total volume of 200 µL. Liberation of AMC at room temperature during 60 min was monitored in a fluorimetric microplate reader (Infinite 200 pro, Tecan) with excitation at 380 nm and emission at 460 nm.

Statistical methods {#s4-11}
-------------------

All experiments were performed at least three times. Statistical analyses were performed using two-tailed Student's t-test to calculate p-values. Statistical analyses on Pearson's correlation coefficients (Rr) were performed using a Fisher r-to-z transformation and then a two-tailed z-test on z values obtained.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"*Shigella* entry unveils a calcium/calpain-dependent mechanism for inhibiting sumoylation\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Ivan Dikic as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Hubert Hilbi (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The study by Lapaquette et al., represents an important advance in our understanding of mechanisms of host-pathogen communication and provides novel insight about how an invasive bacterial pathogen facilitates its uptake.

*Shigella flexneri*, the causative agent of bacillary dysentery hijacks the host ubiquitin-like system SUMOylation, Entry into epithelial cells is an obligatory event for *Shigella* virulence antagonized by SUMOylation. To dissect how *Shigella* interferes with the SUMO system they extend these findings to an in vivo model of infection (newborn mouse). Next, they explore a possible link between hyposumoylation and calcium activated proteases, calpains, which are known to be activated upon *Shigella* infection. The investigators show that upon infection of epithelial cells by *S. flexneri* (i) sumoylation is inhibited, and in turn, sumoylation inhibits bacterial invasion, (ii) the protease calpain and calcium levels regulate sumoylation, (iii) calpain cleaves the SUMO E1 enzyme SAE2, (iv) sumoylation of the Rho GTPase inhibitor RhoGDIα is blocked, and (v) sumoylated proteins and RhoGDIα are recruited to *S. flexneri* entry sites.

In summary, the study provides evidence that *S. flexneri*-triggered activation of calpain cleaves SAE2, reduces sumoylation of RhoGDIα and favors membrane accumulation of active Rho GTPases. Thus, in essence *S. flexneri* stimulates Rho GTPase activity, thereby facilitating cytoskeletal rearrangements and promoting its uptake by non-phagocytic host cells.

Essential revisions:

1\) The authors showed in this and previous studies that (i) calpain cleaves SAE2, (ii) SAE2 knockdown promotes *S. flexneri* entry into host cells, and (iii) sumoylation of RhoGDIα regulates entry. To provide a direct link between SAE2 and RhoGDIα, the authors should assess whether depletion of SAE2 indeed reduces the sumoylation of RhoGDIα during infection with *S. flexneri*. Also, how relevant the observation of global hyposumoylation is in the context of *Shigella* infection as it seems that it is rather a direct response to changed Ca^2+^ levels that is a common consequence of many different stimuli?

2\) It is unclear how the global desumoylation and specific RhoGDIα desumoylation, are linked. Clearly, the RhoGDIα desumoylation is more likely a consequence of increased desumolyation mediated perhaps by some bacterial effector than impaired sumoylation through inhibition of SAE2 by calpain-mediated degradation. Furthermore, the kinetics of the two events is very different with RhoGDIα desumoylation occurring early and global hyposumoylation later post-infection. The authors need to explain how RhoGDIα desumoylation and cytoskeleton rearrangements fit to the global desumoylation effect.

3\) The dependence of RhoGDIα colocalization with *Shigella* on UBC9 is unconvincing. The authors should at least provide quantification of [Figure 7](#fig7){ref-type="fig"}. Also, see comment for [Figure 6: a](#fig6){ref-type="fig"} similar experiment would strengthen the claim that RhoGDIα colocalization with *Shigella* depends on SUMO machinery and sumoylation.

4\) The roles of *Shigella* factors, responsible for mediating the hyposumoylation are not adequately explored. VirA is conspicuous by its absence. A previous report (the one that links *Shigella* infection to calpain activation) reported that *Shigella*-induced calpain activation is VirA dependent. VirA has had multiple activities ascribed to it and this has resulted in a confusing body of literature. In their Discussion they state that they screened a collection of *Shigella* mutants and none of the mutants impaired hyposumoylation. They should show this data, and give some indication as to the nature of the \"collection\". Was it a collection of mutants that they had in house? Was it a library of transposon mutants? How was the experiment done? How many mutants? Was a virA mutant in the collection? The authors need to test if hyposumoylation is induced in a virA mutant and include the findings in this manuscript.

10.7554/eLife.27444.027

Author response

> Essential revisions:
>
> 1\) The authors showed in this and previous studies that (i) calpain cleaves SAE2, (ii) SAE2 knockdown promotes S. flexneri entry into host cells, and (iii) sumoylation of RhoGDIα regulates entry. To provide a direct link between SAE2 and RhoGDIα, the authors should assess whether depletion of SAE2 indeed reduces the sumoylation of RhoGDIα during infection with S. flexneri.

The SAE1/SAE2 heterodimer is the unique E1 enzyme of the SUMO pathway so that loss of SAE1 or SAE2 invariably leads to the complete disappearance of all SUMO conjugates (as shown in [Figure 5A](#fig5){ref-type="fig"} of this study following SAE2 knock down). Moreover, we show that *Shigella* induces an identical loss in SUMO conjugates, including SUMO-RhoGDIα, via a calpain-dependent degradation of SAE2. So depleting SAE2 through siRNA or degrading SAE2 by *Shigella* infection results in the same outcome: global inhibition of sumoylation. We thus did not perform the experiment that would combine both approaches as each one, taken individually, leads to the complete loss in SUMO-modified proteins. However, to address the point raised by the reviewers of the direct link between the loss of SAE2 and the loss of SUMO-RhoGDIα, we depleted SAE2 through siRNA in Hela cells, thus mimicking *Shigella*-induced SAE2 disappearance, and then monitor the basal state of RhoGDIα sumoylation. Even upon forced sumoylation conditions (by overexpression of SUMO1), we observed that a decrease in SAE2 protein level results in a nearly complete loss of sumoylated RhoGDIα, without affecting the level of unmodified form (see [Author response image 1](#respfig1){ref-type="fig"}).

![Sumoylation of RhoGDIα is affected by SAE2 impairment.\
HeLa cells were treated with control siRNA (siScr) or siSAE2, and then co-transferred with expression vectors for GFP-RhoGDIα and SUMO1. Immunoblot analysis was performed on whole cell extracts using anti-GFP, -SAE2 and -Tubulin antibodies. Arrowhead indicates unmodified RhoGDlα and arrow indicates SUMO1- RhoGDIα./[Author response image 1](#respfig1){ref-type="fig"} title/legend\>](elife-27444-resp-fig1){#respfig1}

> Also, how relevant the observation of global hyposumoylation is in the context of Shigella infection as it seems that it is rather a direct response to changed Ca^2+^ levels that is a common consequence of many different stimuli?

This is a strong point and we appreciate the reviewers\' comments here. Beyond the identification of RhoGDIα as an important SUMO substrate targeted by bacteria to enhance infectivity, the finding that global sumoylation can be regulated by modulation of intracellular calcium levels is indeed the second main message of this work. We believe the link between calcium and SUMO signaling discovered here provides a new conceptual framework for the regulatable nature of sumoylation, that goes well beyond the sole infection by *Shigella*. Indeed, as stressed by the reviewers, many physiological and pathological situations are associated with changes in cytosolic calcium levels. This result points out once again to the importance of pathogenic micro-organisms to unveil fundamental biochemical processes of the host cell. Moreover, *Shigella*-induced calcium response is highly specific in terms of kinetics, localization and intensity. Notably, the highly localized nature of the calcium response induced by *Shigella* at early time points of infection (Bonnet and Tran Van Nhieu, 2016) raises the intriguing possibility that sumoylation of a small subset of substrates (including sumoylation of RhoGDIα) can be affected locally during the early stages of infection, suggesting a novel paradigm for sumoylation.

With regards to the relevance of (Ca^2+^-induced) sumoylation inhibition in the context of *Shigella* infection, we had shown previously that sumoylation is an important negative regulator of *Shigella* infectivity (Fritah et al., 2014). Decreasing experimentally the global level of sumoylation in host cells favors *Shigella* spreading in vitro as well as bacterial invasion and intestinal mucosa inflammation in vivo. However, whether *Shigella* indeed targets the global SUMO pathway in host cells was unknown. Here we report that *Shigella* inhibits sumoylation and that this effect is mediated via a Ca^2+^/calpain-induced degradation of SAE2 which in turn facilitates *Shigella*-induced cytoskeletal rearrangements and bacterial entry.

> 2\) It is unclear how the global desumoylation and specific RhoGDIα desumoylation, are linked. Clearly, the RhoGDIα desumoylation is more likely a consequence of increased desumolyation mediated perhaps by some bacterial effector than impaired sumoylation through inhibition of SAE2 by calpain-mediated degradation. Furthermore, the kinetics of the two events is very different with RhoGDIα desumoylation occurring early and global hyposumoylation later post-infection. The authors need to explain how RhoGDIα desumoylation and cytoskeleton rearrangements fit to the global desumoylation effect.

We agree with the reviewers that the link between the global inhibition of sumoylation, the specific loss of SUMO-RhoGDIα and the calpain-induced degradation of SAE2 is an important issue. One may distinguish here the kinetics of loss of SUMO-RhoGDIα, global SUMO conjugates and SAE2.

The loss of SUMO-RhoGDIα coincides with the first visible reduction in the amount of total sumoylated proteins after 30 min ([Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Quantification showing a slight, yet consistant \~25% reduction in the level of SUMO1 conjugates and concomitant accumulation of free SUMO1 after 30 min has been added in the new [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"} and in the Results section. The strong decrease in the total amount of SUMO2-conjugates after 30 min was readily shown in the original [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}. The early global inhibition of sumoylation and the specific loss of SUMO-RhoGDIα are thus directly linked. The rapidity with which the sumoylated form of a given protein is lost is highly specific for the substrate and relies on its half-life and the dynamics of its proper sumoylation/desumoylation equilibrium which also depends on its intracellular localization. The impairment of sumoylation will result in a gradual loss of SUMO conjugates starting with the most sensitive substrates, such as RhoGDIα, and will ultimately affect the most heavily and stably modified ones like RanGAP1. To remove the original ambiguous formulation and make this clearer in the revision, we now mention: "Whereas the levels of unmodified RhoGDIα remained unaffected, we observed the complete disappearance of SUMO-RhoGDIα as quickly as 30 min post-infection ([Figure 8](#fig8){ref-type="fig"}). The reduction in the global amount of SUMO1 conjugates was only moderate in these conditions ([Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), indicating that RhoGDIα is highly sensitive to sumoylation inhibition" (subsection "Endogenous RhoGDIα and SUMO proteins are recruited at bacteria entry sites and *Shigella* rapidly impairs RhoGDIαsumoylation").

We agree with the reviewers that there is an apparent discordance between the loss of SAE2, which is not yet visible 1 h post-infection ([Figure 4C](#fig4){ref-type="fig"}), and the reduction in global sumoylation, that begins 30 min after infection. This point has been now clearly stated in the Results section and extensively discussed (Discussion section). Because of this readily noticeable time lag for SAE2 degradation, we feel that earlier time points between 0 and 1 h would not be really informative. The mechanisms responsible for the early reduction in SUMO conjugates triggered by *Shigella* infection remain to be elucidated. As pointed by the reviewers, *Shigella* may have developed additional strategies to impair sumoylation early during infection, such as activation of desumoylases. However, a direct involvement of increased SENP activities seems unlikely as the loss in SUMO-modified proteins is, like SAE2 loss, strictly dependent on calpains ([Figure 2A-C](#fig2){ref-type="fig"}), and no link has been so far established between calpain and SENP activities. Moreover, we have now measured the global desumoylase activity in *Shigella* M90T non-denatured lysates. Using fluorogenic 7-amino-4-methylcoumarin SUMO substrates (SUMO1-AMC and SUMO2-AMC), we failed to reveal any SUMO1 or SUMO2 protease activities in M90T extracts when compared to recombinant SENP2 used here as a positive control. The data are shown in the new [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.

Since the loss of SAE2 and SUMO conjugates are both calpain-dependent, we favor the hypothesis that the rapid loss of SUMO-RhoGDIα results from the first and localized wave of Ca^2+^ response induced by *Shigella* in the vicinity of the entry sites. This response would lead to a local calpain-induced degradation of a small pull of SAE2, hardly detectable by Western blot, and subsequent loss of highly sensitive SUMO conjugates including SUMO-RhoGDIα. A more definitive clarification of this issue must, however, await the development of probes permitting the visualization of localized sumoylation dynamics. We have modified and expanded the corresponding section in the Discussion section to comment more in depth on this point. Since we cannot strictly rule out that non-SAE2-dependent mechanisms are involved in the early hyposumoylation triggered by *Shigella*, we have also added the word \'mainly\' in the sentence "this effect is mainly mediated by a calcium/calpain-induced cleavage of the SUMO E1 enzyme SAE2" in the Abstract.

> 3\) The dependence of RhoGDIα colocalization with Shigella on UBC9 is unconvincing. The authors should at least provide quantification of [Figure 7](#fig7){ref-type="fig"}. Also, see comment for [Figure 6: a](#fig6){ref-type="fig"} similar experiment would strengthen the claim that RhoGDIα colocalization with Shigella depends on SUMO machinery and sumoylation.

We thank the reviewers for this comment. As requested, quantification has been performed by using the colocalization studio plugin of Icy software (Lagache et al., 2015), enabling the calculation of Pearson\'s correlation coefficients (Rr) between fluorescent signals from SUMO1, SUMO2/3 or RhoGDIα immunostaining and signal from actin foci at *Shigella* entry site. We have included these data as new figure panels 7B, D and F and in the corresponding Results section. Analysis in Ubc9 WT MEFs reveals a moderate positive correlation between SUMO1 (Rr=0.41, p=0.008), SUMO2/3 (Rr=0.36, p=0.025), RhoGDIα (Rr=0.47, p=0.000017) and actin at bacteria entry site (at least 40 entry foci analysed per condition), confirming an enrichment in SUMO1, SUMO2/3 and RhoGDIα at *Shigella* entry foci in Ubc9 WT-infected MEFs. These positive correlations are weaker and lose significance for SUMO1 (Rr=0.226, p=0.073) and SUMO2/3 (Rr=0.290, p=0.082) in Ubc9 KO cells, indicating a decrease in conjugated SUMO signal at *Shigella* entry site in cells depleted in sumoylation. The positive correlation between RhoGDIα immunostaining and *Shigella* entry sites remains statistically unchanged upon loss of sumoylation (Rr= 0.487, p=0.0006), indicating that, in contrast to what we suggested initially, RhoGDIα colocalization with *Shigella* entry foci does not depend on an active SUMO machinery. We have corrected these data in the Results section.

> 4\) The roles of Shigella factors, responsible for mediating the hyposumoylation are not adequately explored. VirA is conspicuous by its absence. A previous report (the one that links Shigella infection to calpain activation) reported that Shigella-induced calpain activation is VirA dependent. VirA has had multiple activities ascribed to it and this has resulted in a confusing body of literature. In their Discussion they state that they screened a collection of Shigella mutants and none of the mutants impaired hyposumoylation. They should show this data, and give some indication as to the nature of the \"collection\". Was it a collection of mutants that they had in house? Was it a library of transposon mutants? How was the experiment done? How many mutants? Was a virA mutant in the collection? The authors need to test if hyposumoylation is induced in a virA mutant and include the findings in this manuscript.

To identify putative *Shigella* factors involved in sumoylation inhibition, we have now used a wider in-house panel of mutant strains: *mxiD, mxiE, ospG, ipaB, ipaC, ipaC*/pC35, *ipaC*/pC57, *ipgD* and *virA*. Data are presented in the new [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}. Among these mutants, the strain mutated for the transcriptional activator MxiE is still able to induce a loss in SUMO conjugates, despite the fact that this mutant is unable to express and secrete numerous *Shigella* effectors and some IpaH proteins encoded by chromosomal genes (Bongrand et al., 2012; Kane et al., 2002; Mavris et al., 2002). Similar observations were made for the strains defective for the IpgD and OspG effectors. In contrast, mutants for the genes encoding the translocator proteins IpaB and IpaC are no longer able to trigger loss of SUMO conjugates, a feature shared with the *mxiD* mutant. These findings indicate the involvement of T3SS-related processes in *Shigella*-induced sumoylation inhibition. Interestingly, IpaB and IpaC proteins act as translocator-forming proteins that are able to target the host plasma membrane. As described in the Discussion section, three pore forming toxins produced by Gram positive bacteria have already been reported to induce a massive loss in SUMO conjugates (Ribet et al., 2010), thus suggesting a similar mechanism for the Gram negative *Shigella*. The use of two insertion mutants of IpaC, *ipaC*/pC57 and *ipaC*/pC351 (Mounier et al., 2009), further revealed that the stress at the plasma membrane triggered by this translocator protein, appears to be sufficient to induce the loss in SUMO conjugates. Indeed, the *ipaC*/pC57 mutant, that is defective for invasion but still able to induce actin foci formation at the host plasma membrane, induces hyposumoylation, whereas the *ipaC*/pC351 mutant, defective for actin foci formation, is unable to do so. Calpain proteases have been amply described to participate in the healing of damaged plasma membranes by allowing local remodeling of the cortical cytoskeleton (Godell et al., 1997; Mellgren et al., 2007; Mellgren et al., 2009). One may thus hypothesize that, by triggering pore formation and subsequent plasma membrane stress, *Shigella* infection induces a calpain-dependent loss of sumoylation. We have included these data as new [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} and in the Results and Discussion sections.

With regards to the effect of VirA pointed out by the reviewers, Bergounioux et al., (2012) have reported that the virA defective strain is still able to induce calpain activation, albeit less rapidly than the wild-type strain. In our hands, the *mxiE* mutant, that lacks expression of VirA, or the *virA* mutant itself were as potent as the wild-type strain to induce calpain activation, SAE2 degradation and the subsequent loss in SUMO1 and SUMO2/3 conjugates 2h post-infection (see [Author response image 2](#respfig2){ref-type="fig"}).

![The virA defective mutant induces calpain activation and loss of SUMO conjugates and SAE2.\
SUMO1 and SUMO2 patterns in HeLa cells, uninfected or infected for 120min with the wild-type *Shigella* strain M90T or mutants *mxiD* or *virA*. Immunoblot analysis was performed on whole-cell lysates using antibodies specific for SUMO1, SUMO2/3, Capns1, SAE2 and Tubulin. Arrows indicate autolytic fragments of Capns1. Tubulin was used as a loading control.](elife-27444-resp-fig2){#respfig2}
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